商品・サービス / 治験結果データベース

  • Font SizeAA


Through our Clinical Trial Outcome Databases we enable clients to capture summary level data for the clinical safety and efficacy outcomes from publicly available data sources. For this, we have collaborated with Quantitative Solutions Inc. (QS) to market the existing QS core Clinical Trial Outcome Databases and to develop/market additional databases in selected disease areas. QS, founded by Jaap Mandema and Russ Wada, is a leading scientific consultancy service provider to the Pharmaceutical and Biotech industry. It develops quantitative models of clinical PK, efficacy and safety data to enable better Drug Development decisions.


clinical trial outcome database


Currently available databases

Key features

Why use CTO Database?

Know more Know more Know more

We have designed these databases to assist clients in conducting comparative efficacy and safety analysis, linking/scaling biomarkers to clinical outcomes, predicting/improving trial outcome and developing product differentiation strategies. They are further supported by customization and M&S consulting services provided by GVK BIO and QS, respectively, to ensure maximum flexibility and benefits.

Available databases

  • Rheumatoid Arthritis
  • Osteoporosis
  • Neuropathic Pain
  • HCV
  • Schizophrenia
  • Alzheimer’s
  • Dyslipidemia
  • Diabetes
  • Glaucoma
  • H1 Launch
    • Multiple Sclerosis (Breast Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC)
    • Low Back Pain

Key Features

  • Comprehensiveness:Includes information for marketed drugs as well as drugs in development; data sources include journal publications, conference posters, regulatory reviews, etc.
  • Ease of tracking:All clinical trial publications are listed in a separate database and linked to unique clinical trial names.
  • Flexibility:Design allows for quick updates and expansions to include additional indications/drugs/endpoints/trials.
  • Model-friendliness:Designed and reviewed by experts having the highest quality and usability for development strategies.
  • Customizability:Can be augmented with clinical trial data proprietary to the client (this information goes into a separate proprietary database and will be owned by the client)


  • Designed and managed by experienced modelers with strong expertise in meta-analysis
  • Supported by multiple clients and proven valuable in drug development decision making
  • Updated semi-annually to enable time and decisions
  • Backed by GVK BIO custom curation services and consulting services offered by QS